Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HTR3A | P46098 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699881 | 0.91 | DRD2 (0.47) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4701351 | 0.90 | HTR6 (0.42) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4698755 | 0.90 | HTR1A (0.46) | DRD2HTR2CHTR6HTR2AKHK | |
| SCHEMBL4703667 | 0.87 | HTR1A (0.53) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4700434 | 0.86 | HTR2C (0.52) | HTR2CHTR6HTR2AHTR7KHK | |
| SCHEMBL4701205 | 0.86 | HTR2C (0.42) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4698501 | 0.85 | HTR2C (0.44) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4698675 | 0.85 | HTR2C (0.55) | DRD2HTR2CHTR6KHKHTR1A | |
| SCHEMBL4698914 | 0.84 | DRD2 (0.49) | DRD2HTR2CHTR6HTR2AHTR7 | |
| SCHEMBL4698796 | 0.84 | HTR1A (0.47) | DRD2HTR2CHTR6HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | claimed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | claimed |
| JP-2006522029-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1613594-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087662-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | claimed |
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | disclosed |
| EP-1613594-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087662-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | TPH1, HTR2C, HTR1D | DRD2 19/4885HTR2C 2/4885HTR6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.